Surgical site infections are considered one of the dangerous complications of surgical procedures, accounting for nearly 20% of all hospital-acquired infections (HAIs). They have a pooled prevalence of 2.5% to 41.9% worldwide and significantly affect low and middle-income countries, especially patients in intensive care units (ICU). The increasing cases of surgical site infections are augmenting the demand for preventive and therapeutic solutions. Moreover, the rise in antibiotic-resistant bacteria is propelling the need for alternative treatments, thereby driving innovation in the drug pipeline.
The Surgical Site Infection (SSI) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into surgical site infection (SSI) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for surgical site infection (SSI). The surgical site infection (SSI) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The surgical site infection (SSI) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with surgical site infection (SSI) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to surgical site infection (SSI).
A surgical site infection (SSI) is a type of healthcare-associated infection (HAI) that occurs at the site of surgery. It exposes the patient to substantial healthcare costs as a result of severe morbidity and longer hospital stays along with the increased risk of death. Risk factors for surgical site infection include poor nutritional state, anemia, age, and obesity, among others.
Surgical site infection (SSI) therapeutics include broad-spectrum antibiotics and narrow-spectrum antibiotics targeting the specific pathogen identified through culture and sensitivity testing. Surgical site infection (SSI) emerging drugs like biologics, such as monoclonal antibodies, help in enhancing immune response and prevent infections. Further, the growing focus on non-antibiotic therapies, such as bacteriophage treatments and probiotic-based approaches, to address antibiotic resistance is anticipated to support the drug pipeline expansion in the coming years.
A 2023 systematic review and meta-analysis found the global incidence of surgical site infections (SSIs) to be 2.5%. Subgroup analysis showed an incidence of 2.7% by WHO region and 2.5% by the survey period. The African region reported the highest incidence of surgical site infections. Further, the pooled prevalence is estimated to be 2.5% to 41.9% worldwide.
This section of the report covers the analysis of surgical site infection (SSI) drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of surgical site infection (SSI) drugs undergoing clinical development.
The drug molecule categories covered under the surgical site infection (SSI) pipeline analysis include small molecules, monoclonal antibodies (mAbs), peptides, antimicrobial agents, and other biologics. The surgical site infection (SSI) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for surgical site infection (SSI).
The EMR report for the surgical site infection (SSI) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed surgical site infection (SSI) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in surgical site infection (SSI) clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by PolyPid Ltd., the objective of this randomized clinical trial is to investigate the efficacy and safety of the surgical site infection (SSI) drug candidate D-PLEX in the prevention of post-abdominal surgery incisional infection. The study is under Phase III clinical development and has an estimated 624 participants.
Baylor College of Medicine is conducting a Phase IV study aimed at examining the efficacy and safety...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The Surgical Site Infection (SSI) Drug Report provides a strategic overview of the latest and future landscape of treatments for surgical site infection (SSI). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within surgical site infection (SSI) pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share